Enoxaparin sodium is an anticoagulant heparin with a low molecular weight drug (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to treat and prevent blood clots during pregnancy and after certain types of surgery. Pulmonary embolism occurs when blood clots move through the lungs and get stuck in the blood vessels of lungs. This medication is prescribed for a period of time after knee or hip replacement surgery, as well as in some cases of abdominal surgery and also in the event of a major illness. Moreover, enoxaparin sodium is used in those with acute coronary syndrome (ACS) and heart attack. It is injected into a vein or just beneath the skin. Bleeding, fever, and leg swelling are all common adverse effects. Bleeding might be dangerous, especially if an individual is having a spinal tap.
COVID-19 Impact Analysis
- COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global enoxaparin sodium market.
Top Impacting Factors
Increasing prevalence of heart diseases and rising cases of deep vein thrombosis & pulmonary embolism related health problems propel the market growth of enoxaparin sodium market.
Rising number of surgeries and increasing need for preventing any complications boost the market growth.
Increase in number of Food and Drug Administration approval drugs and surge in the geriatric population are some factors, which boost the market growth.
Rise in awareness for the treatment of several cardiovascular disease fuels the market growth.
In addition, increase in healthcare expenditure, rise in research & development activities conducted by many pharmaceutical companies, launches of novel developed drug in market are some factors which contribute toward the enoxaparin sodium market growth.
However, side effects associated with enoxaparin sodium and availability of alternative drugs are expected to hamper the enoxaparin sodium market growth.
Market Trends
New Product Launches to Flourish the Market
- In March 2019, Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted approval of its Abbreviated New Drug Application (ANDA) for enoxaparin sodium injection 300mg/3mL (100mg/mL) multiple dose vial (MDV).
- In May 2021, Sandoz Canada launched its sixth biosimilar, Inclunox (enoxaparin sodium), an anticoagulant used to treat deep vein thrombosis, in the Canadian market. Inclunox is a biosimilar for Lovenox, a blood thinning medication used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism during pregnancy and following certain surgeries.
- Surge in Usage of Enoxaparin Sodium
- Increasing incidence of deep vein thrombosis and pulmonary embolism across the world boosts the usage of enoxaparin sodium. According to medscape, in 2019 death from deep vein thrombosis (DVT) -associated massive pulmonary embolism (PE) causes as many as 300,000 deaths annually in the U.S. It is the third most common cardiovascular disease and is associated with substantial short- and long-term morbidity and mortality.
Key Benefits of the Report
- This study presents the analytical depiction of the enoxaparin sodium market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the enoxaparin sodium market share.
- The current market is quantitatively analyzed to highlight the enoxaparin sodium market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Enoxaparin Sodium Market Report
- Which are the leading market players active in the enoxaparin sodium market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What future projections would help in taking further strategic steps?
- What is enoxaparin sodium market?
- What is enoxaparin sodium market prediction in the future?
- Who are the leading global players in the enoxaparin sodium market?
- What are the current trends and predicted trends?
- What are the key benefits of the enoxaparin sodium market report?
Enoxaparin Sodium Market Report Highlights
| Aspects | Details |
 By Drug Type |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Meitheal Pharmaceuticals, Inc., Sanofi, NorthStar Rx, Apotex Inc., Sanodz, Biocon Limited, Shenzhen Techdow Pharmaceutical Co., Ltd, Teva Pharmaceutical Industries Limited, Themis Medicare Limited, Fresenius Kabi |
Loading Table Of Content...
